Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 85-89 , April 2010

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: No shortcuts on the road to approval

  • Caroline J. Breitbach

      Affiliations

    • Jennerex Inc., San Francisco, CA, USA
    • ,
  • Tony Reid

      Affiliations

    • University of California, San Diego Cancer Center, La Jolla, CA, USA
    • ,
  • James Burke

      Affiliations

    • Billings Clinic, Billings, MT, USA
    • ,
  • John C. Bell

      Affiliations

    • Jennerex Inc., San Francisco, CA, USA
    • Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada
    • Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada
    • ,
  • David H. Kirn

      Affiliations

    • Jennerex Inc., San Francisco, CA, USA
    • Corresponding Author InformationCorresponding author at: Jennerex Inc. 201 Mission Suite 1380, San Francisco, CA 94105, USA.

References 

  1. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Landmark article Sept. 21, 1946. Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA. 1984;251(May (17)):2255–2261
  2. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(February (9)):645–652
  3. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6(September (9)):519–527
  4. Check Hayden E. Cancer complexity slows quest for cure. Nature. 2008;455(September (7210)):148
  5. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9(January (1)):64–71
  6. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 2001;93(June (12)):903–912
  7. Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest. 2005;115(February (2)):379–387
  8. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther. 2007;15(September (9)):1686–1693
  9. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007;4(February (2)):101–117
  10. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther. 2008;16(September (9)):1637–1642
  11. Parato KA, Lichty BD, Bell JC. Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther. 2009;11(February (1)):13–21
  12. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008;8(October (10)):1581–1588
  13. Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?. Curr Opin Mol Ther. 2008;10(February (1)):32–37
  14. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(June (6)):533–542
  15. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(October (10)):569–579
  16. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(December (34)):5763–5771
  17. Flaherty K, Puzanov I, Sosman J, Kim A, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. ASCO; 2009. J Clin Oncol, ASCO annual meeting proceedings (post-meeting edition); 2009.
  18. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin Cancer Res. 2008;14(November (21)):7127–7137
  19. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(April (4)):651–659

PII: S1359-6101(10)00012-2

doi: 10.1016/j.cytogfr.2010.02.001

Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 85-89 , April 2010

Article Tools

* Image Usage & Resolution